HOME
ABOUT
PRODUCT DEVELOPMENT
MEDICAL CANNABIS
- SCIENCE
- LEGALISED MARKETS
INVESTORS
- ASX ANNOUNCEMENTS
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
- PRESENTATIONS & VIDEOS
  - 2019
  - 2018
  - 2017
  - 2016
  - 2015
- REPORTS
- STOCK INFORMATION
- CORPORATE GOVERNANCE
MEDIA
CONTACT

HOME
ABOUT
PRODUCT DEVELOPMENT
MEDICAL CANNABIS
- - SCIENCE
- - LEGALISED MARKETS
INVESTORS
- - ASX ANNOUNCEMENTS
  - - 2020
  - - 2019
  - - 2018
  - - 2017
  - - 2016
- - PRESENTATIONS & VIDEOS
  - - 2019
  - - 2018
  - - 2017
  - - 2016
  - - 2015
- - REPORTS
- - STOCK INFORMATION
- - CORPORATE GOVERNANCE
MEDIA
CONTACT

REPORTS

REPORTS

Date	Title
24/01/2019	Viriathus Research Report, 13 September 2018

SUBSCRIBE

Leave this field empty if you're human:

Zelira TherapeuticsFollow

24 Feb

Results from the phase 1b/2a clinical trial showed treatment with ZTL-101 medical cannabis formulation achieved a statistically significant improvement in Insomnia Severity Index scores #zeliratherapeutics #investor #medicinalcannabis #insomnia #clinicaltrial #ZLD